Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le dimanche 05.04.2020 à 10:00 AM CEST
Paramétrages

Paramétrages

1. WO2005004861 - UTILISATION DE NOUVEAUX COMPOSES 2-OXO-HETEROCYCLIQUES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES

Numéro de publication WO/2005/004861
Date de publication 20.01.2005
N° de la demande internationale PCT/KR2004/001764
Date du dépôt international 15.07.2004
CIB
A61K 31/4015 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
33Composés hétérocycliques
395ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
40ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
4015ayant des groupes oxo liés directement à l'hétérocycle, p.ex. piracétam, éthosuximide
CPC
A61K 31/4015
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4015having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 207/38
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
30having two double bonds between ring members or between ring members and non-ring members
34with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
36Oxygen or sulfur atoms
382-Pyrrolones
C07D 211/86
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
80having two double bonds between ring members or between ring members and non-ring members
84with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
86Oxygen atoms
C07D 223/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
223Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
02not condensed with other rings
06with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
08Oxygen atoms
10attached in position 2
Déposants
  • KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR/KR]; 52, Eoeun-dong, Yuseong-gu Daejeon 305-806, KR (AllExceptUS)
  • DAEWOONG PHARMACEUTICAL CO., LTD. [KR/KR]; 223-23, Sangdaewon-dong, Jungwon-gu, Seongnam-si Gyeonggi-do 462-807, KR (AllExceptUS)
  • HAN, Gyoon Hee [KR/KR]; KR (UsOnly)
  • KIM, Hwan Mook [KR/KR]; KR (UsOnly)
  • PARK, Song Kyu [KR/KR]; KR (UsOnly)
  • LEE, Chang Woo [KR/KR]; KR (UsOnly)
  • HAN, Sang Bae [KR/KR]; KR (UsOnly)
  • LEE, Ki Hoon [KR/KR]; KR (UsOnly)
  • KHO, Yung Hee [KR/KR]; KR (UsOnly)
  • YANG, Jin Hyuk [KR/KR]; KR (UsOnly)
  • PARK, Bum Woo [KR/KR]; KR (UsOnly)
  • LEE, Hyang Woo [KR/KR]; KR (UsOnly)
  • HAN, Jeung Whan [KR/KR]; KR (UsOnly)
  • RYU, Dong Kyu [KR/KR]; KR (UsOnly)
  • LEE, Jin Ha [KR/KR]; KR (UsOnly)
  • CHUN, Tae Gyu [KR/KR]; KR (UsOnly)
  • KIM, Yong Kee [KR/KR]; KR (UsOnly)
  • LEE, Hee Yoon [KR/KR]; KR (UsOnly)
  • LEE, Bong Yong [KR/KR]; KR (UsOnly)
  • KIM, Jeom Yong [KR/KR]; KR (UsOnly)
  • KIM, Ji Duck [KR/KR]; KR (UsOnly)
  • YU, Kyunga [KR/KR]; KR (UsOnly)
  • KIM, Sun Young [KR/KR]; KR (UsOnly)
Inventeurs
  • HAN, Gyoon Hee; KR
  • KIM, Hwan Mook; KR
  • PARK, Song Kyu; KR
  • LEE, Chang Woo; KR
  • HAN, Sang Bae; KR
  • LEE, Ki Hoon; KR
  • KHO, Yung Hee; KR
  • YANG, Jin Hyuk; KR
  • PARK, Bum Woo; KR
  • LEE, Hyang Woo; KR
  • HAN, Jeung Whan; KR
  • RYU, Dong Kyu; KR
  • LEE, Jin Ha; KR
  • CHUN, Tae Gyu; KR
  • KIM, Yong Kee; KR
  • LEE, Hee Yoon; KR
  • LEE, Bong Yong; KR
  • KIM, Jeom Yong; KR
  • KIM, Ji Duck; KR
  • YU, Kyunga; KR
  • KIM, Sun Young; KR
Mandataires
  • SHIN, Dong In; 304, Dukam Building 1457-2 Seocho3-dong Seocho-gu Seoul 137-867, KR
Données relatives à la priorité
10-2003-004815315.07.2003KR
10-2003-004815415.07.2003KR
10-2004-005271307.07.2004KR
10-2004-005271407.07.2004KR
10-2004-005271507.07.2004KR
10-2004-005271607.07.2004KR
10-2004-005271807.07.2004KR
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
(FR) UTILISATION DE NOUVEAUX COMPOSES 2-OXO-HETEROCYCLIQUES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
Abrégé
(EN)
The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the cancer disease comprising lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphonas, cancer of the bladder, cancer of the kidney or ureter, or neoplasms of the central nervous system, therefore, it can be used as the therapeutics for treating and preventing cancer diseases.
(FR)
L'invention concerne une nouvelle utilisation de composés 2-oxo-hétérocycliques présentant une activité anticancéreuse, ainsi que le procédé permettant de préparer ces composés et une composition pharmaceutique les contenant. L'invention concerne également une composition pharmaceutique destinée à la prévention et au traitement des pathologies cancéreuses, notamment des cancers des poumons, des cancers osseux, des cancers du pancréas, des cancers de la peau, des cancers affectant la tête et le cou, des mélanomes cutanés ou intraoculaires, des cancers utérins, des cancers de l'ovaire, des cancers du rectum ou de la région anale, des cancers de l'estomac, du colon, du sein et des tumeurs gynécologiques, de la maladie de Hodgkin, des cancers de l'oesophage, de l'intestin grêle, du système endocrinien, des sarcomes des tissus mous, des cancers de l'urètre, du pénis, de la prostate, des leucémies chroniques ou aiguës, des tumeurs solides de l'enfant, des lymphomes lymphocytiques, des cancers de la vessie, des cancers des reins ou de l'uretère, ou des néoplasmes du système nerveux central, et indiquée par conséquent pour le traitement ou la prévention des pathologies cancéreuses.
Également publié en tant que
Dernières données bibliographiques dont dispose le Bureau international